Strides Shasun gets USFDA nod for anti-HIV drug Abacavir
- B-schools have to refund fees if student cancels before admissions close: AICTE
- BK Birla group’s Kesoram Industries to get Rs350 crore from promoters
- Supreme Court gives Jaypee till 25 January to deposit Rs125 crore
- Caution, vigilance warranted on inflation front: RBI governor Urjit Patel
- Why the Fox deal may resurrect Disney’s film business in India
Hyderabad: Strides Shasun Ltd on Tuesday said it got approval from US Food and Drug Administration (USFDA) for anti-retroviral Abacavir tablets used in the treatment of patients with HIV infection.
Strides said the US approval is for 300 mg dosage form.
The product will be manufactured at the company’s USFDA approved facility at Bengaluru and marketed by Strides in the US market, the company said in a statement.
“The product will be launched immediately,” it added.
According to IMS sales data, the US market for Abacavir is approximately $30 million.
Shares of Strides rose 1.31% to close at Rs1,056.70 on BSE, while the benchmark Sensex declined 0.19% to 27,876.61 points.